List of Amicus Therapeutics patents

Patents where

Current Assignee

Name

Amicus Therapeutics

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10155027 Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease	Patent 10155027 was granted and assigned to Amicus Therapeutics on December, 2018 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10155027	December 18, 2018
‌ US Patent 10076514 Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene	Patent 10076514 was granted and assigned to Amicus Therapeutics on September, 2018 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10076514	September 18, 2018
‌ US Patent 11833164 Methods of treating Fabry disease in patients having a mutation in the GLA gene	Patent 11833164 was granted and assigned to Amicus Therapeutics on December, 2023 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11833164	December 5, 2023
‌ US Patent 11623916 Highly purified batches of pharmaceutical grade migalastat and methods of producing the same	Patent 11623916 was granted and assigned to Amicus Therapeutics on April, 2023 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11623916	April 11, 2023
‌ US Patent 10251873 Methods of treating fabry patients having renal impairment	Patent 10251873 was granted and assigned to Amicus Therapeutics on April, 2019 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10251873	April 9, 2019
‌ US Patent 10537564 Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene	Patent 10537564 was granted and assigned to Amicus Therapeutics on January, 2020 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10537564	January 21, 2020
‌ US Patent 10357548 α-galactosidase A and 1-deoxygalactonojirimycin co-formulation	Patent 10357548 was granted and assigned to Amicus Therapeutics on July, 2019 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10357548	July 23, 2019
‌ US Patent RE48608 Method to predict response to pharmacological chaperone treatment of diseases	Patent RE48608 was granted and assigned to Amicus Therapeutics on June, 2021 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	RE48608	June 29, 2021
‌ US Patent 11786516 Methods of treating Fabry patients having renal impairment	Patent 11786516 was granted and assigned to Amicus Therapeutics on October, 2023 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11786516	October 17, 2023
‌ US Patent 11666564 Methods of treating Fabry patients having renal impairment	Patent 11666564 was granted and assigned to Amicus Therapeutics on June, 2023 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11666564	June 6, 2023
‌ US Patent 10471053 Methods of treating Fabry patients having renal impairment	Patent 10471053 was granted and assigned to Amicus Therapeutics on November, 2019 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10471053	November 12, 2019
‌ US Patent 9545450 Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases	Patent 9545450 was granted and assigned to Amicus Therapeutics on January, 2017 by the United States Patent and Trademark Office.		Amicus Therapeutics	United States Patent and Trademark Office	9545450	January 17, 2017
‌ US Patent 10383864 Methods for treatment of Fabry disease	Patent 10383864 was granted and assigned to Amicus Therapeutics on August, 2019 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10383864	August 20, 2019
‌ US Patent 10406143 Methods for treatment of fabry disease	Patent 10406143 was granted and assigned to Amicus Therapeutics on September, 2019 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10406143	September 10, 2019
‌ US Patent 10525045 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones	Patent 10525045 was granted and assigned to Amicus Therapeutics on January, 2020 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10525045	January 7, 2020
‌ US Patent 11491211 Formulations comprising recombinant acid alpha-glucosidase	Patent 11491211 was granted and assigned to Amicus Therapeutics on November, 2022 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11491211	November 8, 2022
‌ US Patent 11357784 Use of migalastat for treating Fabry disease in pregnant patients	Patent 11357784 was granted and assigned to Amicus Therapeutics on June, 2022 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11357784	June 14, 2022
‌ US Patent 9279007 Signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins	Patent 9279007 was granted and assigned to Amicus Therapeutics on March, 2016 by the United States Patent and Trademark Office.		Amicus Therapeutics	United States Patent and Trademark Office	9279007	March 8, 2016
‌ US Patent 11304940 Methods of treating Fabry patients having renal impairment	Patent 11304940 was granted and assigned to Amicus Therapeutics on April, 2022 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11304940	April 19, 2022
‌ US Patent 10925866 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones	Patent 10925866 was granted and assigned to Amicus Therapeutics on February, 2021 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	10925866	February 23, 2021
‌ US Patent 11389436 Methods of treating fabry patients having renal impairment	Patent 11389436 was granted and assigned to Amicus Therapeutics on July, 2022 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11389436	July 19, 2022
‌ US Patent 11357765 Methods of treating Fabry patients having renal impairment	Patent 11357765 was granted and assigned to Amicus Therapeutics on June, 2022 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11357765	June 14, 2022
‌ US Patent 11278540 Methods of treating Fabry patients having renal impairment	Patent 11278540 was granted and assigned to Amicus Therapeutics on March, 2022 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11278540	March 22, 2022
‌ US Patent 11278537 Methods of treating Fabry patients having renal impairment	Patent 11278537 was granted and assigned to Amicus Therapeutics on March, 2022 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11278537	March 22, 2022
‌ US Patent 11278536 Methods of treating Fabry patients having renal impairment	Patent 11278536 was granted and assigned to Amicus Therapeutics on March, 2022 by the United States Patent and Trademark Office.	Amicus Therapeutics	Amicus Therapeutics	United States Patent and Trademark Office	11278536	March 22, 2022

...

Results per page:

138 results

0 selected

138 results

0 selected